EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY
https://doi.org/10.15789/1563-0625-2008-4-5-477-482
Abstract
Abstract. Recently discovered immune–modulating and anti-inflammatory properties of statins have resulted in application of these drugs for treatment of autoimmune disorders. There are few studies investigating therapeutic potential of simvastatin in rheumatoid arthritis (RA). In present study, we investigated efficacy and safety of simvastatin in active RA patients treated with conventional disease-modifying antirheumatic drugs (DMARDs). Thirty-three patients were enrolled into an open-label, controlled study. The patients received treatment with 40 mg of simvastatin daily for 12 weeks. A group of historical controls consisted of nine patients taking placebo combined with disease-modifying therapy. No differences in demographic characteristics and disease activity were observed between the two groups. By the end of therapy (12 weeks), simvastatin-treated patients exhibited a significant reduction in disease activity scores with 28-joint counts (DAS28), and according to physician’s assessment of disease, as compared with control group. The estimate of trea tment effect (DAS28 scores) was 0.76 (95% confidence interval 0.01-1.5), thus corresponding to moderate decrease in disease activity. In conclusion, combination therapy with simvastatin and conventional DMARDs results into decreased RA activity. However, additional studies are required in order to specify exact role of simvastatin in RA treatment. (Med. Immunol., vol. 10, N 4-5, pp 477-482).
About the Authors
I. V. Shirinsky
ГУ «Научно-исследовательский институт клинической иммунологии СО РАМН», г. Новосибирск
Russian Federation
Russian Federation
O. I. Zheltova
ГУ «Научно-исследовательский институт клинической иммунологии СО РАМН», г. Новосибирск
Russian Federation
Russian Federation
V. S. Shirinsky
ГУ «Научно-исследовательский институт клинической иммунологии СО РАМН», г. Новосибирск
Russian Federation
Russian Federation
V. A. Kozlov
ГУ «Научно-исследовательский институт клинической иммунологии СО РАМН», г. Новосибирск
Russian Federation
Russian Federation
References
1. Ширинский И.В., Ширинский В.С. Ингибирование 3-гидрокси-3-метилглутарил коэнзим А редуктазы снижает активацию лимфоцитов у больных ревматоидным артритом за счет снижения концентрации изопреноидов // Мед. иммунология. – 2007. – T. 9, № 2-3. – С. 357.
2. Фаллер Д.М., Шилдс Д. Молекулярная биология клетки. – М.: Бином-Пресс, 2006. – 256 с.
3. Aktas O., Waiczies S., Smorodchenko A., Dorr J., Seeger B., Prozorovski T., Sallach S., Endres M., Brocke S., Nitsch R., Zipp F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin // J. Exp. Med. – 2003. – Vol. 197. – P. 725-733.
4. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis // Arthritis Rheum. – 1988. – Vol. 31, N 3. – P. 315-324.
5. Azuma R.W., Suzuki J., Ogawa M., Futamatsu H., Koga N., Onai Y., Kosuge H., Isobe M. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation // Cardiovasc. Res. – 2004. – Vol. 64. – P. 412-420.
6. Barsante M.M., Roffe E., Yokoro C.M., Tafuri W.L., Souza D.G., Pinho V., Castro M.S., Teixeira M.M. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis // Eur. J. Pharmacol. – 2005. – Vol. 516. – P. 282-289.
7. Cohen J. A power primer // Psychol. Bull. – 1992. – Vol. 112. – P. 155-159.
8. Dessein P.H., Stanwix A.E., Joffe B.I. Cardio-vascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis // Arthritis Res. – 2002. – Vol. 4. – P. R5.
9. Fries J.F., Spitz P., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis // Arthritis Rheum. – 1980. – Vol. 23. – P. 137-145.
10. Georgiadis A.N., Papavasiliou E.C., Lourida E.S., Alamanos Y., Kostara C., Tselepis A.D., Drosos A.A. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study // Arthritis Res Ther. – 2006. – Vol. 8. – P. R82.
11. Greenwood J., Steinman L., Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation // Nat. Rev. Immunol. – 2006. – Vol. 6. – P. 358-370.
12. Hakamada-Taguchi R., Uehara Y., Kurib-ayashi K., Numabe A., Saito K., Negoro H., Fujita T., Toyooka T., Kato T. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development // Circ. Res. – 2003. – Vol. 93. – P. 948-956.
13. Kanda H., Hamasaki K., Kubo K., Tateishi S., Yonezumi A., Kanda Y., Yamamoto K., Mimura T. Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis // J. Rheumatol. – 2002. – Vol. 29. – P. 2024-2026.
14. Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., Madhok R., Campbell C., Gracie J.A., Liew F.Y., McInnes I.B. A novel anti-inflammatory role for simvastatin in inflammatory arthritis // J. Immunol. – 2003. – Vol. 170. – P. 1524-1530.
15. Liu W., Li W.M., Gao C., Sun N.L. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats // J. Autoimmun. – 2005. – Vol. 25. – P. 258-263.
16. McCarey D.W., McInnes I.B., Madhok R., Hampson R., Scherbakov O., Ford I., Capell H.A., Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial // Lancet. – 2004. – Vol. 363. – P. 2015-2021.
17. Prevoo M.L., van 't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis // Arthritis Rheum. – 1995. – Vol. 38. – P. 44-48.
18. Sena A., Pedrosa R., Graca Morais M. Therapeutic potential of lovastatin in multiple sclerosis // J. Neurol. – 2003. – Vol. 250. – P. 754-755.
19. Shirinsky I.V., Shirinsky V.S. Efficacy of simvastatin in plaque psoriasis: а pilot study // J. Am. Acad. Dermatol. – 2007. – Vol. 57. – P. 529-531.
20. Shirinsky I.V., Zheltova O.I., Shirinsky V.S. Efficacy and safety of simvastatin in the treatment of rheumatoid arthritis // Ann. Rheum. Dis. – 2007. – Vol. 66 (suppl. II). – P. 448.
21. van Gestel A.M., Prevoo M.L., van 't Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria // Arthritis Rheum. – 1996. – Vol. 39. – P. 34-40.
22. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., Cottens S., Takada Y., Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site // Nat. Med. – 2001. – Vol. 7. – P. 687-692.
Review
For citations:
Shirinsky I.V., Zheltova O.I., Shirinsky V.S., Kozlov V.A. EFFICACY AND SAFETY OF SIMVASTATIN IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL, CONTROLLED STUDY. Medical Immunology (Russia). 2008;10(4-5):477-482. (In Russ.) https://doi.org/10.15789/1563-0625-2008-4-5-477-482
Views:
809
Email this article 